Dr. Reddys Laboratories announced on Friday that it has launched raloxifene hydrochloride tablets in the US market.
Raloxifene hydrochloride is a therapeutic equivalent generic version of Evista tablets in the US market, which has approval of the US Food and Drug Administration (USFDA) — the country’s health regulator, Dr. Reddy’s said in a statement.
The Evista brand and generic of Eli Lilly and Company “had registered sales of approximately $265 million MAT in the US in the most recent twelve months ending in September 2016 according to IMS Health”, said the Hyderabad-based company which operates in markets across the globe.
Dr. Reddys raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.
The drug is used in treatment and prevention of osteoporosis, invasive breast cancer in postmenopausal women.